 |
|
|
Hypercard 10 Tablets (pack of 30) |
|
Hypercard 10 mg is indicated for the therapeutic treatment of feline primary hypertrophic cardiomyopathy. Diltiazem Hydrochloride is a benzothiazepine derivative which acts as a Calcium channel blocker and exerts its effect by selectively inhibiting the inward movement of Calcium ions across the cell membrane into vascular smooth muscle cells and myocardial cells.
|
|
Presentation
Yellow coated biconvex tablets each containing Diltiazem hydrochloride PhEur 10 mg.
Excipient(s)
Tartrazine E102 0.11 mg per tablet
Titanium Dioxide, Cl No. 77891 (E171) 1.1 mg per tablet
Sodium Propyl hydroxybenzoate, (E217) 1.67 µg per tablet
Sodium Methyl hydroxybenzoate, (E219) 1.67 µg per tablet
Uses
HyperCard 10 is indicated for the therapeutic treatment of Feline Primary Hypertrophic Cardiomyopathy. Diltiazem Hydrochloride is a benzothiazepine derivative which acts as a calcium channel blocker and exerts its effect by selectively inhibiting the inward movement of calcium ions across the cell membrane into vascular smooth muscle cells and myocardial cells.
|
|
Dosage and administration
Oral
1 tablet per cat (weighing 3.0 – 6.25 kg bodyweight) every eight hours (equivalent to 1.6 – 3.3mg diltiazem hydrochloride per kg every 8 hours). Treatment should be given for the life of the animal.
|
|
Contra-indications, warnings, etc
Do not use in animals suffering from AV block (2nd or 3rd), hypotension or sick sinus syndrome.
Monitor glucose levels carefully in diabetic animals.
Diltiazem should not be given to patients suffering from hepatic disease.
Do not use in animals suffering from renal disease.
Do not use in cats less than 12 months old.
Do not use in cats weighing less than 3 kg.
Do not use in animals that are hypersensitive to Diltiazem.
Do not use in cats with severe bradycardia or arterial hypotension.
Do not use in conjunction with β blockers, Digitalis or Digoxin.
Do not use in pregnant or lactating queens. Studies of laboratory animals have shown evidence of teratogenic and embryotoxic effects.
Concurrent use with Cimetidine or any other histamine 2 receptor antagonists may cause an increase in plasma Diltiazem concentrations.
Use with caution in conjunction with other calcium channel blockers, anticonvulsant drugs, immunosuppressant drugs, lithium, neuromuscular blocking agents and aminoglycoside antibiotics.
Use with caution in cats suffering from congestive heart failure.
Cats with possible pre-existing thyroid problems or hyperthyroidism should be treated for this first and then reassessed prior to commencing treatment with Diltiazem.
Clinical examination to assess the effectiveness of treatment should be performed after 8 weeks.
Cardiac rate should be monitored prior to treatment commencing and at every follow up visit.
Some lethargy can occur at the beginning of treatment.
May cause occasional minor gastro-intestinal problems, eg. constipation, and anorexia. Rashes, skin reactions and erythema are potential side effects of Diltiazem.
Bradycardia, hypotension and conduction abnormalities may occasionally occur.
Gaseous anaesthetics such as halothane, isoflurane or enflurane have synergistic or additive effects with Diltiazem, which may lead to hypotension, depressed myocardial contractile function, slow junctional rhythm and AV block. Therefore animals treated with Hypercard 10 and undergoing gaseous anaesthesia should be monitored closely.
In case of overdose, carry out gastric lavage and dose with activated charcoal.
For bradycardia and heart block, treat with normal saline infusion and vasopressors (Atropine, Dopamine or Isoprenaline).
Observations in humans have indicated that treatment with calcium may be useful in treating toxicity from calcium channel blocker overdose.
Dispose of used packaging in the household refuse. Unused product should be returned to the veterinary surgeon.
General precautions
Wash hands after use as tartrazine in the colour coating may cause allergic reaction in people who are susceptible. Keep out of the reach of children. For animal treatment only.
Do not break tablets.
In case of accidental ingestion, seek medical advice immediately and show the package insert to the physician.
Pharmaceutical precautions
Do not store above 25°C.
|
|
Legal category
POM-V (previously POM).
Packaging Quantities
Blister packs of 30 tablets.
Further information
Nil.
Marketing authorisation number
Vm 01732/4104.
|
|
|
